Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Aytu Biopharma (AYTU) over the last 5 years, with Sep 2025 value amounting to $206,800.

  • Aytu Biopharma's Gains from Investment Securities rose 46.21% to $206,800 in Q3 2025 from the same period last year, while for Sep 2025 it was $206,800, marking a year-over-year increase of 46.21%. This contributed to the annual value of $211,618 for FY2025, which is 44.41% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Gains from Investment Securities is $206,800, which was down 78.75% from $973,000 recorded in Q4 2024.
  • Aytu Biopharma's Gains from Investment Securities' 5-year high stood at $1.0 million during Q2 2024, with a 5-year trough of -$2.7 million in Q2 2021.
  • Its 3-year average for Gains from Investment Securities is $178,740, with a median of $152,061 in 2023.
  • Data for Aytu Biopharma's Gains from Investment Securities shows a peak YoY increase of 4,182.26% (in 2023) and a maximum YoY decrease of 96,300.00% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Gains from Investment Securities stood at $277,000 in 2021, then crashed by 72.92% to $75,000 in 2022, then spiked by 4,182.26% to $162,683 in 2023, then decreased by 13.06% to $973,000 in 2024, then surged by 46.21% to $206,800 in 2025.
  • Its Gains from Investment Securities stands at $206,800 for Q3 2025, versus $973,000 for Q4 2024 and $141,439 for Q3 2024.